H
Howard Jenkins
Researcher at Royal Derby Hospital
Publications - 5
Citations - 1141
Howard Jenkins is an academic researcher from Royal Derby Hospital. The author has contributed to research in topics: Population & Annual Screening. The author has an hindex of 5, co-authored 5 publications receiving 960 citations. Previous affiliations of Howard Jenkins include University of Sussex.
Papers
More filters
Journal ArticleDOI
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Ian Jacobs,Ian Jacobs,Ian Jacobs,Usha Menon,Andy Ryan,Aleksandra Gentry-Maharaj,Matthew Burnell,Jatinderpal Kalsi,Nazar Najib Amso,Sophia Apostolidou,Elizabeth Benjamin,Derek Cruickshank,Danielle N. Crump,Susan K Davies,Anne Dawnay,Stephen Dobbs,Gwendolen Fletcher,Jeremy Ford,Jeremy Ford,Keith M. Godfrey,Richard Gunu,Mariam Habib,Mariam Habib,Rachel Hallett,Rachel Hallett,Jonathan Herod,Howard Jenkins,Chloe Karpinskyj,Simon Leeson,Sara Lewis,William R. Liston,Alberto Lopes,Tim Mould,Tim Mould,John Murdoch,David H. Oram,Dustin J. Rabideau,K. Reynolds,Ian Scott,Mourad W. Seif,Mourad W. Seif,A. Sharma,A. Sharma,Naveena Singh,Julie Taylor,Fiona Warburton,Fiona Warburton,Martin Widschwendter,Karin Williamson,Robert Woolas,Robert Woolas,Lesley Fallowfield,Alistair McGuire,Stuart Campbell,Mahesh K. B. Parmar,Steven J. Skates +55 more
TL;DR: Although the mortality reduction was not significant in the primary analysis, it was noted a significant mortality reduction with MMS when prevalent cases were excluded, and encouraging evidence of a mortality reduction in years 7–14 was noted.
Journal ArticleDOI
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort
Ian Jacobs,Aleksandra Gentry-Maharaj,Matthew Burnell,Ranjit Manchanda,Naveena Singh,A. Sharma,Andrew M. Ryan,Mourad W Seif,Nazar Najib Amso,Gillian Turner,Carol Brunell,Gwendolen Fletcher,Rani Rangar,Kathy Ford,Keith M. Godfrey,Alberto Lopes,David H. Oram,Jonathan Herod,Karin Williamson,Ian A Scott,Howard Jenkins,Tim Mould,Robert Woolas,John Murdoch,Stephen Dobbs,Simon Leeson,Derek Cruickshank,Steven J. Skates,Lesley Fallowfield,Mahesh K. B. Parmar,Stuart Campbell,Usha Menon +31 more
TL;DR: The findings show that TVS screening for endometrial cancer has good sensitivity in postmenopausal women, and the burden of diagnostic procedures and false-positive results can be reduced by limiting screening to a higher-risk group.
Journal ArticleDOI
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening
Usha Menon,Andy Ryan,J Kalsi,Aleksandra Gentry-Maharaj,Anne Dawnay,Mariam Habib,Sophia Apostolidou,Naveena Singh,Elizabeth Benjamin,M Burnell,Susan K Davies,A. Sharma,Richard Gunu,K. A. Godfrey,Alberto Lopes,David Oram,Jonathan Herod,Karin Williamson,Mourad W. Seif,Howard Jenkins,Tim Mould,Robert Woolas,John Murdoch,Stephen Dobbs,Nazar Najib Amso,Simon Leeson,Derek Cruickshank,Ian Scott,Lesley Fallowfield,Martin Widschwendter,K. Reynolds,Alistair McGuire,Stuart Campbell,Mahesh M K Parmar,Steven J. Skates,Ian Jacobs,Ian Jacobs +36 more
TL;DR: Screening by using ROCA doubled the number of screen-detected iEOCs compared with a fixed cutoff, suggesting reliance on predefined single-threshold rules may result in biomarkers of value being discarded in the context of cancer screening.
Journal ArticleDOI
Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials
Matthew Burnell,Aleksandra Gentry-Maharaj,Andrew M. Ryan,Sophia Apostolidou,Mariam Habib,Jatinderpal Kalsi,Steven J. Skates,Mahesh K. B. Parmar,Mourad W Seif,Nazar Najib Amso,Keith M. Godfrey,David H. Oram,Jonathan Herod,Karin Williamson,Howard Jenkins,Tim Mould,Robert Woolas,John Murdoch,Stephen Dobbs,Simon Leeson,Derek Cruickshank,Stuart Campbell,Lesley Fallowfield,Ian Jacobs,Usha Menon +24 more
TL;DR: Recruitment to screening trials through invitation from population registers does not prevent a pronounced HVE on mortality and the impact on cancer incidence is much smaller, and it maybe prudent to use the various mortality and incidence rates presented as guides for calculating event rates and power in RCTs involving women.
Journal ArticleDOI
Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomized Controlled Trial
Ian Jacobs,Usha Menon,Andrew M. Ryan,Aleksandra Gentry-Maharaj,Matthew Burnell,Jatinderpal Kalsi,Nazar Najib Amso,Sophia Apostolidou,Elizabeth Benjamin,Derek Cruickshank,Danielle N. Crump,Susan K Davies,Anne Dawnay,Stephen Dobbs,Gwendolen Fletcher,Jeremy Ford,Keith M. Godfrey,Richard Gunu,Mariam Habib,Rachel Hallett,Jonathan Herod,Howard Jenkins,Chloe Karpinskyj,Simon Leeson,Sara Lewis,William R. Liston,Alberto Lopes,Tim Mould,John Murdoch,David E. Oram,Dustin J. Rabideau,K. Reynolds,Ian A Scott,Mourad W. Seif,A. Sharma,Naveena Singh,Julie Taylor,Fiona Warburton,Martin Widschwendter,Karin Williamson,Robert Woolas,Lesley Fallowfield,Alistair McGuire,Stuart Campbell,Mahesh K. B. Parmar,Steven J. Skates +45 more
TL;DR: The primary study outcome was death due to OC by December 31, 2014, and the relative mortality reduction over years 0 to 14 was 15% (95% confidence interval, −3 to 30; P = 0.10) with MMS and 11% (−7 to 27) with USS.